On March 20, 2024, RetinalGenix Technologies Inc. closed the transaction. The transaction included participation from 25 investors. The company paid $3,500,000 as sales commissions in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +4.63% | +0.89% | +30.23% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.23% | 42.5M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- UNCY Stock
- News Unicycive Therapeutics, Inc.
- Unicycive Therapeutics, Inc. announced that it has received $50 million in funding